L-tyrosine
An amino acid in protein foods, also sold as N-acetyl-L-tyrosine (NALT)
An amino acid found in protein foods such as cheese, meat, fish and beans, and studied mostly for thinking and memory under stress, such as cold, heat or a night without sleep. Here is every study in people we could find, sorted, and the trials that are free online read in full.
- Found in: cheese, meat, fish and beans
- Often dosed by body weight
- Often a single dose
From every paper to the studies that matter
Most papers on tyrosine are about its role in the body, not about taking it. The studies in people are mostly of three kinds. Many give one large dose before a hard task. Many older ones are tyrosine load tests, which measured how the body clears a big dose, often in thyroid or liver disease. Smaller groups look at inherited conditions such as PKU, and only a few last a week or more.
-
16,484 papers mention tyrosine.Every record in PubMed, all years
-
356 are about people.The rest: 7,502 lab and animal studies, 485 reviews, 8,141 on chemistry, farming and more
-
135 give L-tyrosine or NALT on its own.43 more test it inside a blend, often with other amino acids
-
61 are randomised against a placebo.Randomised controlled trials In a randomised controlled trial, people are put into groups by chance, one taking the treatment and one a placebo or other comparison. Chance spreads differences such as age and health evenly, so a difference between the groups is more likely to be down to the treatment., the strongest kind of study
-
17 read in full so far.Every number checked against the paper
Bar lengths use a square-root scale so the small numbers stay visible.
How much research there is
- 135 studies giving L-tyrosine to people
- 61 of them randomised against a placebo A placebo-controlled trial compares a real treatment with a dummy that looks the same, the placebo. People often feel better when they expect to, so comparing against a placebo shows how much of the change comes from the treatment itself.
- 1,824 people taking part, where studies say
- 38 systematic reviews A systematic review searches for every study on a question in a set, written-down way, judges the quality of each and sums up what they show together. Many include a meta-analysis. The Atlas lists these as pooled reviews. pooling the trials
Studies in people, by year published
L-tyrosine or NALT on its own.
What the studies looked at
Each study can measure several things. Choose a topic to see its studies in the list below.
Studies in people with a diagnosed condition are counted here and listed with their population. We describe what they measured, not what they might treat. Most studies also report safety; see below.
What was tested, and how much
L-tyrosine is a single compound, so milligrams compare directly. But most studies gave one dose sized to body weight, often 100 to 150 mg per kg (about 7 to 10 g for a 70 kg adult), and only studies with a set daily dose appear on this chart. Supplements also sell it as N-acetyl-L-tyrosine (NALT). The few studies of NALT in people gave it by drip, and much of it passed out unchanged in urine.
Daily amount, one dot per study
Studies per extract
Named extracts are the maker's brand. "Not named" means the study didn't say.
Have a label to check? Work out the L-tyrosine in your own label
All studies in people
Filter the list, then open a study on PubMed. A result shows once we've read the full paper. Older studies with no summary online were sorted from the title.
| Study | Who took part | People | Extract and daily dose | Length | Result |
|---|---|---|---|---|---|
| Lin 2026Single-arm or open-label | Healthy adults | 48 | Not named | – | Not read in full yet |
| Matsumoto 2026Crossover, placebo | Healthy community-dwelling men aged 20-60 years (mean age 43.4, BMI 23.2) recruited in Osaka, without chronic disease, thyroid disorders or MAOI use | 30 | Not named, 1,000 or 2,000 or 3,000 or 4,000 mg | 4 weeks | Unclear |
| Bilgin 2026Crossover, placebo | Professional male football players aged 18-30 (mean 24.2 years) from the Turkish third tier (TFF 3. Lig), tested after a Wingate fatigue protocol | 24 | Not named | – | Unclear |
| Solon-Júnior 2026Crossover, placebo | Recreationally trained male cyclists (level 3; mean age 32 years) cycling to exhaustion after a 60-min Stroop task to induce mental fatigue | 14 | Not named | – | Positive result |
| Averdunk 2026Single-arm or open-label | Children with YARS1 deficiency | 9 | Not named | – | Not read in full yet |
| Donnan 2025Crossover, placebo | Well-trained male student soccer players (mean age 19.75 years) exercising in heat (32 C, 50% rh) | 8 | Not named | – | No difference |
| McAllister 2024RCT, placebo | Healthy young adults, mental stress challenge | 80 | Not named, 2,000 mg | – | Not read in full yet |
| Hart 2024RCT, placebo | Adolescents aged 12-17 years with anorexia nervosa (DSM-IV; <85%, later <95%, weight for height) in inpatient and community child and adolescent mental health services; 6 girls and 1 boy randomised | 7 | Not named, 5,000 mg | 12 weeks | Unclear |
| Mathar 2022Crossover, placebo | Healthy right-handed non-smoking men without psychiatric or neurological illness, medication or drug use | 30 | Not named, 2,000 mg | – | Mixed results |
| Lim 2021RCT, placebo | Healthy university students (mean age 22.8 years; 32 women, 16 men) without cardiac, hepatic, renal, neurological or psychiatric illness, addiction, or previous tyrosine or GABA supplement use | 48 | Not named, 2,000 mg | – | No difference |
| Hart 2021Pharmacokinetic | Adolescents with anorexia nervosa and healthy peers | 4 | Not named | 12 weeks | Not read in full yet |
| Robson 2020RCT, placebo | Healthy university students (mean age 19.9; 59 women, 11 men) | 70 | Not named, 2,000 mg | – | Harm reported |
| Jongkees 2020Crossover, placebo | Healthy young adults aged 18-30 (25 of 45 women, all using hormonal contraception) | 45 | Not named, 2,000 mg | – | No difference |
| Ahrens 2020RCT, placebo | Healthy non-smoking adults aged 18-35 (analysed mean age about 24) | 45 | Not named, 2,000 mg | – | Mixed results |
| Froböse 2020Crossover, placebo | Healthy right-handed older adults (inclusion 60-75; completers aged 61-71, mean 66.7; 16 men) | 33 | Not named | – | No difference |
| Lang 2020Crossover, placebo | Healthy young and older adults, cold exposure | 18 | Not named | – | Not read in full yet |
| Tumilty 2020Crossover, placebo | Recreationally trained men, warm environment | 8 | Not named | – | Not read in full yet |
| Soranzo 2019RCT, placebo | Healthy university students (analysed sample mean age 20.4; 25 women, 21 men) | 56 | Not named, 2,000 mg | – | Unclear |
| Dennison 2019Crossover, placebo | Healthy university students (mean age 20.8; 15 women, 9 men) | 24 | Not named, 2,000 mg | – | Mixed results |
| Bloemendaal 2018Crossover, placebo | Healthy older adults (inclusion 60-75; analysed sample aged 61-72, mean 67.5; 15 men, 9 women) | 33 | Not named | – | No difference |
| Stock 2018Crossover, placebo | Young healthy adults | 26 | Not named | – | Not read in full yet |
| Lang 2017Crossover, placebo | Healthy young and older adults, cold exposure | 22 | Not named | – | Not read in full yet |
| Israely 2017Crossover, placebo | Hospitalised women with chronic anorexia nervosa | 19 | Not named | 3 weeks | Not read in full yet |
| Coull 2016RCT, placebo | Healthy adults in heat stress | 21 | Not named | – | Not read in full yet |
| Colzato 2016RCT, placebo | Healthy adults by DRD2 genotype | – | Not named | – | Not read in full yet |
| Lieberman 2015RCT, placebo | Healthy US Navy and Marine personnel (72 men, 6 women, mean age 25) in the mock-captivity phase of Survival, Evasion, Resistance, and Escape (SERE) School, including two mock interrogations | 78 | Not named | – | Harm reported |
| Steenbergen 2015RCT, placebo | Healthy adults | 22 | Not named | – | Not read in full yet |
| Coull 2015Crossover, placebo | Male soccer players | 8 | Not named | – | Not read in full yet |
| Colzato 2015RCT, placebo | Healthy adults, creativity tasks | – | Not named | – | Not read in full yet |
| DiFrancisco-Donoghue 2014RCT, placebo | Adults aged 45-79 with Parkinson's disease taking L-dopa and diagnosed with orthostatic hypotension | 40 | Not named, 1,000 mg | 1 weeks | No difference |
| Dowlati 2014RCT, placebo | Healthy breastfeeding women | 24 | Not named, 10,000 mg | – | Not read in full yet |
| Tumilty 2014Crossover, placebo | Endurance-trained men, exercise in heat | 7 | Not named | – | Not read in full yet |
| Colzato 2014Crossover, placebo | Healthy adults | – | Not named | – | Not read in full yet |
| Jongkees 2014Other | Healthy adults | – | Not named | – | Not read in full yet |
| Kishore 2013Crossover, placebo | Healthy young men, heat exposure | 10 | Not named, 6,500 mg | – | Not read in full yet |
| Colzato 2013Other | Healthy adults | – | Not named | – | Not read in full yet |
| Watson 2012Crossover, placebo | Healthy young men, exercise in heat | 8 | Not named | – | Not read in full yet |
| Tumilty 2011Crossover, placebo | Healthy trained men, heat exercise | 8 | Not named | – | Not read in full yet |
| Lang 2010Other | Young and older healthy adults | 20 | Not named | – | Not read in full yet |
| Badaloo 2010Other | Children recovering from severe undernutrition | 13 | Not named | – | Not read in full yet |
| Belza 2009Crossover, placebo | Healthy normal-weight men | 12 | Not named, 400 mg | – | Not read in full yet |
| Rafii 2008Other | Healthy adult men on controlled diet | 6 | Not named | – | Not read in full yet |
| Palinkas 2007RCT, placebo | Healthy adults living in Antarctica | 43 | Not named, 12,000 mg | 20 weeks | Not read in full yet |
| Mahoney 2007Crossover, placebo | Healthy male and female military research volunteers aged 18-35 (mean age 20.5) exposed to repeated cold-water immersion | 19 | Not named | – | Mixed results |
| O'Brien 2007Crossover, placebo | Healthy subjects in cold water | 15 | Not named | – | Not read in full yet |
| Sutton 2005Crossover, placebo | Healthy men in load-carriage test | 20 | Not named | – | Not read in full yet |
| Waters 2003RCT, placebo | Healthy young men, sleep-deprived | 76 | Not named | – | Not read in full yet |
| Hoffer 2003Other | Adults on parenteral nutrition | 13 | N-acetyl-L-tyrosine | – | Not read in full yet |
| Magill 2003RCT, placebo | Healthy young men, sleep-deprived | – | Not named | – | Not read in full yet |
| Cui 2003Other | Youths exercising at 3700 m altitude | – | Not named | – | Not read in full yet |
| Chinevere 2002Crossover, placebo | Competitive male cyclists | 9 | Not named | – | Not read in full yet |
| Kalsner 2001Pharmacokinetic | People with phenylketonuria on diet | 10 | Not named | – | Not read in full yet |
| Roberts 2001Other | Healthy men | 6 | Not named | – | Not read in full yet |
| Thorpe 2000Other | Healthy men | – | Not named | – | Not read in full yet |
| Deijen 1999RCT, active or other control | Military cadets in combat training | 21 | Not named | – | Not read in full yet |
| Thomas 1999Crossover, placebo | Healthy men and women | 20 | Not named | – | Not read in full yet |
| Wiesel 1999Non-randomised controlled | Patients with schizophrenia and healthy controls | 10 | Not named | – | Not read in full yet |
| Smith 1998Crossover, placebo | People with phenylketonuria aged 6-28 | 21 | Not named | 4 weeks | Not read in full yet |
| Strüder 1998Crossover, placebo | Healthy trained male cyclists | 10 | Not named, 20,000 mg | – | Not read in full yet |
| Lines 1997Other | People with phenylketonuria | – | Not named | – | Not read in full yet |
| Galloway 1996Single-arm or open-label | Cocaine-dependent outpatients | 49 | Not named, 6,000 mg | 13 weeks | Not read in full yet |
| Pietz 1995Crossover, placebo | Adults with phenylketonuria | 24 | Not named | 4 weeks | Not read in full yet |
| Dollins 1995Crossover, placebo | Healthy adults, lower body negative pressure | 20 | Not named | – | Not read in full yet |
| Druml 1995Pharmacokinetic | Hepatic failure patients and healthy adults | 13 | N-acetyl-L-tyrosine | – | Not read in full yet |
| Neri 1995RCT, placebo | Healthy adults, one night without sleep | – | Not named | – | Not read in full yet |
| Deijen 1994Crossover, placebo | Healthy young adults under noise stress | 16 | Not named | – | Not read in full yet |
| Shurtleff 1994Crossover, placebo | Healthy men, cold exposure | 8 | Not named | – | Not read in full yet |
| Clayton 1994Crossover, placebo | Healthy male volunteers given ethanol | – | Not named | – | Not read in full yet |
| Deutsch 1994Crossover, placebo | Schizophrenia inpatients on molindone | – | Not named, 10,000 mg | 3 weeks | Not read in full yet |
| Christensen 1993Pharmacokinetic | Infants on pediatric amino acid solution | – | N-acetyl-L-tyrosine | – | Not read in full yet |
| Wässer 1992Crossover, placebo | Children with phenylketonuria | 8 | Not named | 13 weeks | Not read in full yet |
| Mazzocco 1992Other | School-aged children with phenylketonuria | – | Not named | – | Not read in full yet |
| Druml 1991Pharmacokinetic | Hemodialysis patients and healthy controls | 15 | N-acetyl-L-tyrosine | – | Not read in full yet |
| Gelenberg 1990RCT, placebo | Outpatients with major depression | 65 | Not named | 4 weeks | Not read in full yet |
| Magnusson 1989Other | Healthy volunteers | 11 | N-acetyl-L-tyrosine, 5,000 mg | – | Not read in full yet |
| Lemoine 1989Single-arm or open-label | Parkinson's disease patients | 10 | Not named | 156 weeks | Not read in full yet |
| Elwes 1989Crossover, placebo | People with narcolepsy and cataplexy | 10 | Not named, 9,000 mg | 4 weeks | Not read in full yet |
| Dissing 1989Single-arm or open-label | Parkinson's disease patients | 5 | Not named, 15,000 mg | 7 weeks | Not read in full yet |
| Carlson 1989Other | Normal subjects | – | Not named | – | Not read in full yet |
| Banderet 1989Crossover, placebo | Healthy volunteers exposed to cold and hypoxia | – | Not named | – | Not read in full yet |
| Mouret 1988Single-arm or open-label | Patients with dopamine-dependent depression | 12 | Not named, 3,200 mg | – | Not read in full yet |
| Mouret 1988Single-arm or open-label | Narcolepsy patients | 8 | Not named | 26 weeks | Not read in full yet |
| Al-Damluji 1988Crossover, placebo | Healthy men | 8 | Not named | – | Not read in full yet |
| Eisenberg 1988Single-arm or open-label | Children with ADHD | 7 | Not named | – | Not read in full yet |
| Lou 1987Non-randomised controlled | Phenylketonuria patients aged 15-24 | 14 | Not named | – | Not read in full yet |
| Reimherr 1987Single-arm or open-label | Adults with attention deficit disorder | 12 | Not named | 8 weeks | Not read in full yet |
| Kondo 1987Single-arm or open-label | Juvenile parkinsonism patients and relatives | – | Not named | – | Not read in full yet |
| Wernze 1986Non-randomised controlled | Cirrhosis patients and healthy controls | 28 | Not named, 14,000 mg | 0 weeks | Not read in full yet |
| Lieberman 1985Crossover, placebo | Healthy young men | 20 | Not named | – | Not read in full yet |
| Cuche 1985Other | Healthy men | 15 | Not named | – | Not read in full yet |
| Sole 1985Crossover, placebo | Adults with mild essential hypertension | 13 | Not named, 7,500 mg | 2 weeks | Not read in full yet |
| Kvittingen 1985Other | Two healthy adults with low enzyme activity | 2 | Not named | – | Not read in full yet |
| Ni 1985Other | Adult men | – | Not named | – | Not read in full yet |
| Raw 1984Non-randomised controlled | Congenital pain insensitivity patients and controls | – | Not named | – | Not read in full yet |
| Lieberman 1984RCT, placebo | Unclear | – | Not named | – | Not read in full yet |
| Johnston 1983Non-randomised controlled | Normal-weight and obese women | 21 | Not named | 1 weeks | Not read in full yet |
| Ishizuka 1983Other | Healthy men | 7 | Not named | – | Not read in full yet |
| Benedict 1983RCT, active or other control | Healthy male volunteers | – | Not named, 7,500 mg | – | Not read in full yet |
| Yamaguchi 1983Non-randomised controlled | Parkinson's disease patients and healthy controls | – | Not named | – | Not read in full yet |
| Rasmussen 1983RCT, placebo | Healthy fasted men | – | Not named | – | Not read in full yet |
| Leathwood 1982Crossover, placebo | Healthy volunteers | 60 | Not named, 500 mg | – | Not read in full yet |
| Growdon 1982Single-arm or open-label | Parkinson's disease patients | 23 | Not named | – | Not read in full yet |
| Alonso 1982Non-randomised controlled | Human volunteers | – | Not named | – | Not read in full yet |
| Agharanya 1981Single-arm or open-label | Healthy volunteers | 11 | Not named | 0 weeks | Not read in full yet |
| Antener 1981Non-randomised controlled | Malnourished young mothers and healthy controls | – | Not named | – | Not read in full yet |
| Melamed 1980Single-arm or open-label | Healthy volunteers | 11 | Not named | 0 weeks | Not read in full yet |
| Hoskins 1980Other | Depression patients | – | Not named | – | Not read in full yet |
| Gelenberg 1980Other | Depression patients | – | Not named | – | Not read in full yet |
| Nordlinger 1979Non-randomised controlled | Cirrhotic patients and controls | 26 | Not named | – | Not read in full yet |
| Glaeser 1979Pharmacokinetic | Human volunteers | – | Not named | – | Not read in full yet |
| Zinsser 1973Other | Humans, oxalate excretion | – | Not named | – | Not read in full yet |
| Tarlow 1972Pharmacokinetic | Child with Hartnup variant and coeliac disease | 1 | Not named | – | Not read in full yet |
| Barrera 1971Other | Humans, taste threshold test | – | Not named | – | Not read in full yet |
| Williams 1971Other | Thyroid disease patients | – | Not named | – | Not read in full yet |
| Cavagnini 1970Other | Humans, plasma insulin | – | Not named | – | Not read in full yet |
| Calne 1970Other | Humans, sympathetic nerve function | – | Not named | – | Not read in full yet |
| Modignani 1970Other | Hyperthyroid patients | – | Not named | – | Not read in full yet |
| Braham 1969Non-randomised controlled | Parkinson's disease patients and controls | – | Not named | – | Not read in full yet |
| Fox 1968Other | Thyroid disease patients | – | Not named | – | Not read in full yet |
| Besser 1968Other | Thyroid disease patients | – | Not named | – | Not read in full yet |
| Lotti 1968Non-randomised controlled | Thyroid disease patients and normal subjects | – | Not named | – | Not read in full yet |
| Levine 1967Non-randomised controlled | Liver disease patients and normal subjects | – | Not named | – | Not read in full yet |
| Farran 1966Other | Thyrotoxicosis patients | – | Not named | – | Not read in full yet |
| Kalliomäki 1966Other | Rheumatoid arthritis patients | – | Not named | – | Not read in full yet |
| RIVLIN 1965Other | Thyrotoxicosis and myxedema patients | – | Not named | – | Not read in full yet |
| Tolbert 1963Other | Women on minimal tyrosine diet | – | Not named | – | Not read in full yet |
| VARTIAINEN 1962Non-randomised controlled | Patients with Addison's disease | – | Not named | – | Not read in full yet |
| HUANG 1961Pharmacokinetic | Human subjects | – | Not named | – | Not read in full yet |
| LEVERTON 1956Other | Young women | – | Not named | – | Not read in full yet |
| ROSE 1955Other | Adult volunteers | – | Not named | – | Not read in full yet |
| SPICKARD 1954Other | Allergic patients | – | Not named | – | Not read in full yet |
| VARTIANINEN 1953Other | Human subjects | – | Not named | – | Not read in full yet |
| FERRERO 1950Other | Chronic polyarthritis patients | – | Not named | – | Not read in full yet |
| WOOLF 1950Other | Premature infants | – | Not named | – | Not read in full yet |
| CARRIE 1950Pharmacokinetic | Human subjects | – | Not named | – | Not read in full yet |
What's known about safety
-
In trials
In a 4-week trial of up to 4 g a day in 30 healthy men, side effects were no more common than with placebo. Nearly every other study gave a single dose, so long-term use is little studied.
Matsumoto 2026, 4-week trial at 1 to 4 g a day; Hase 2015, review of 15 studies, all but one a single dose
-
In the UK
Amino acids such as L-tyrosine can be used in food supplements. We found no official UK or EU upper limit. Norway's food safety committee judged 1,250 to 2,000 mg a day from supplements may carry a risk, based on a rat study, as long-term studies in people were lacking.
FSA food supplements guidance; EU Novel Food Status Catalogue, no entry for tyrosine or NALT; VKM 2016, Norway; searches of FSA and EFSA, Oct 2026
-
Check first
It isn't known whether it's safe in pregnancy or breastfeeding, it hasn't been studied for safety in healthy children, and how it mixes with medicines isn't well studied. Speak to a pharmacist or doctor first if any of these applies to you.
VKM 2016, Norway, no data in pregnancy, breastfeeding or children; no UK guidance found, Oct 2026
Where these studies come from
We list every published study of L-tyrosine and NALT in people. Trials that are free online are read in full; the rest are listed from their summaries.
-
We search
PubMed, the world's main library of medical research, for every paper on L-tyrosine.
-
We keep studies in people
Lab and animal work is counted but left out of the list, because it doesn't tell you what happens in people.
-
We note the basics
Who took part, how many, how much and for how long, from each study's published summary, or from the full paper once we've read it. A second check corrects what the first read gets wrong.
-
We read them in full
Results appear once we've read the whole paper and checked every number. The date at the top shows when this entry was last updated.
Download the study list
Every study in people as a spreadsheet, 135 rows, free to reuse with a link back.
Versions
Each update to the data gets a new version number, so you can tell what changed and when.
See every version
1.4 · 8 Nov 2026. The result for one study shows again after a recheck found its paper's slip doesn't change it.
1.3 · 8 Nov 2026. Results for three studies with contradicting numbers now show Unclear.
1.2 · 7 Nov 2026. 17 studies read in full. One removed after a recheck.
1.1 · 3 Nov 2026. Four removed after a recheck.
1.0 · 19 Oct 2026. First release. Every published study giving L-tyrosine on its own to people is listed from its summary. None is read in full yet.